Japan evaluates the economic impact of medical devices through cost-effectiveness analysis, often using metrics like quality-adjusted life years (QALYs) and cost-benefit ratios. Chuikyo and MHLW assess how devices improve healthcare outcomes while controlling costs. Evidence of long-term savings, efficiency, and value compared to existing treatments is crucial for NHI reimbursement decisions.
